Neelam V. Desai - Concepedia

Author

Neelam V. Desai

Harvard University ORCID

Also Known As

N Desai, N. Desai, Neelam Desai, Neelam V Desai, Neelam V. Desai, Neelam Vijay Desai, Schnitt, Stuart J

Publications

782

Citations

H-Index

Concepts

All Affiliations

Harvard University Beth Israel Deaconess Medical Center Dana-Farber Brigham Cancer Center Dana-Farber Cancer Institute Pennsylvania State University

About

Neelam V. Desai is an author at Harvard University specializing in medicine, pathology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	359
2	Cell Biology	4	4	248
3	Immunology	3	3	92
4	Health Sciences	2	2	72
5	Natural Sciences	1	1	133

Neelam V. Desai

Publications

647

Citations

H-Index

Page 1

	Year	Citations
Protein kinase A regulates RNA polymerase III transcription through the nuclear localization of Maf1 Robyn D. Moir, Jae Hoon Lee, Rebecca A. Haeusler, Proceedings of the National Academy of Sciences Transcriptional RegulationSignal TransductionSignaling PathwayMolecular RegulationNatural Sciences	2006	133
Two Steps in Maf1-dependent Repression of Transcription by RNA Polymerase III Neelam V. Desai, Jae Hoon Lee, Rajendra Upadhya, Journal of Biological Chemistry	2004	112
Bif-1 haploinsufficiency promotes chromosomal instability and accelerates Myc-driven lymphomagenesis via suppression of mitophagy Yoshinori Takahashi, Tsukasa Hori, Timothy K. Cooper, Blood	2013	76
Regulation of EBNA gene transcription in lymphoblastoid cell lines: characterization of sequences downstream of BCR2 (Cp) Maryann T. Puglielli, Neelam V. Desai, Samuel H. Speck Journal of Virology Viral ReplicationMolecular RegulationImmunologyImmunotherapyLymphoblastoid Cell Lines	1997	42
Bif-1 suppresses breast cancer cell migration by promoting EGFR endocytic degradation Kristin B. Runkle, Cheryl L. Meyerkord, Neelam V. Desai, Cancer Biology & Therapy Egfr ExpressionBreast OncologyCancer BiologyTumor BiologySignaling Pathway	2012	39
A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer Adrienne G. Waks, Neelam V. Desai, Tianyu Li, npj Breast Cancer	2022	39
De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors Xiuning Le, Neelam V. Desai, Adnan Majid, Lung Cancer MedicinePathologyEgfr InhibitorsBronchial NeoplasmPulmonary Blastoma	2015	34
Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk‐based testing of those older than 60 years Neelam V. Desai, Siddhartha Yadav, Felipe Batalini, Cancer Genetic TestingBreast OncologyCancer RiskNccn CriteriaMedicine	2020	34
Assessment of the HER2DX Assay in Patients With <i>ERBB2</i>-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab Adrienne G. Waks, Esther R. Ogayo, Laia Paré, JAMA Oncology	2023	34
Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial. Laura M. Spring, Sara M. Tolaney, Neelam V. Desai, Journal of Clinical Oncology Breast OncologyCancer ManagementImmunologyPathologyImmunotherapeutics	2022	33

Page 1